LADX Stock Overview
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
LadRx Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.10 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$0.63 |
| Beta | 1.67 |
| 1 Month Change | 13.51% |
| 3 Month Change | 14.75% |
| 1 Year Change | -74.07% |
| 3 Year Change | -99.00% |
| 5 Year Change | -96.25% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LADX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.2% | -3.9% | -3.1% |
| 1Y | -74.1% | -1.8% | 20.9% |
Return vs Industry: LADX underperformed the US Biotechs industry which returned -0.2% over the past year.
Return vs Market: LADX underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| LADX volatility | |
|---|---|
| LADX Average Weekly Movement | 27.2% |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LADX's share price has been volatile over the past 3 months.
Volatility Over Time: LADX's weekly volatility has decreased from 38% to 27% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 2 | Stephen Snowdy | www.ladrxcorp.com |
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer. Further, the company’s Linker Activated Drug Release technology platform consists of an organic backbone, as well as develops albumin companion diagnostic to identify patients with cancer.
LadRx Corporation Fundamentals Summary
| LADX fundamental statistics | |
|---|---|
| Market cap | US$1.26m |
| Earnings (TTM) | US$331.63k |
| Revenue (TTM) | n/a |
3.1x
P/E Ratio0.0x
P/S RatioIs LADX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LADX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | -US$331.63k |
| Earnings | US$331.63k |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.67 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LADX perform over the long term?
See historical performance and comparison